Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects

This publication has 12 references indexed in Scilit:

• Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity
  Pharmacogenomics, 2004
• Treatment for Adult HIV Infection
  JAMA, 2004
• Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
  Biochemical and Biophysical Research Communications, 2004
• Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with Efavirenz
  Clinical Infectious Diseases, 2004
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
  Clinical Infectious Diseases, 2003
• Simultaneous Quantitative Assay of Six HIV Protease Inhibitors, One Metabolite, And Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma by Isocratic Reversed-Phase Liquid Chromatography
  Therapeutic Drug Monitoring, 2002
• Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans
  Clinical Pharmacology & Therapeutics, 2002
• Gender difference in ifosfamide metabolism by human liver microsomes
  European Journal of Drug Metabolism and Pharmacokinetics, 2001
• Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
  The Journal of Clinical Pharmacology, 2001